Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pirtenidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.54 |
| ▸ | KCNA3 known ✓ | P22001 | 3/20 | 0.36 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | HTT | P42858 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | GALR3 | O60755 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octenidine SCHEMBL986183 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL8824299 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL10573899 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL126751 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL126065 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Hydrochloric Acid SCHEMBL10573221 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| Octenidine SCHEMBL16836483 | 1.00 | NPC1 (0.54) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL23393769 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10569601 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA | |
| SCHEMBL10570053 | 0.98 | NPC1 (0.56) | NPC1RAB9AHTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0174632-B1 | ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF | STERLING DRUG INC. (US) | 1990-02-07 | — | — | EP | claimed |
| US-4598082-A | DENTISTRY | STERLING DRUG INC. (US) | 1986-07-01 | — | — | US | claimed |
| EP-0174632-A1 | Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof | STERLING DRUG INC. (US) | 1986-03-19 | — | — | EP | claimed |
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | Bio Logic Crop Science S.L. (ES) | 2025-01-16 | — | — | US | disclosed |
| EP-4427745-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-11766364-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023079206-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science S.L. (ES) | 2023-05-11 | — | — | WO | disclosed |
| US-11452641-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220296422-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220296423-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3989865-A1 | WOUND CLOSURE SYSTEMS FOR REDUCING SURGICAL SITE INFECTIONS COMPRISING INCISION DRAPES FILLED WITH RELEASABLE ANTIMICROBIAL AGENTS | Ethicon, Inc (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3672942-A1 | OCTENIDINE BASED COMPOUNDS | Dishman Carbogen Amcis Ltd. (IN) | 2020-07-01 | — | — | EP | disclosed |
| CN-111051285-A | Octenidine-based compounds | 迪氏曼卡博金艾美斯有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019038669-A1 | OCTENIDINE BASED COMPOUNDS | DISHMAN CARBOGEN AMCIS LTD. (IN) | 2019-02-28 | — | — | WO | disclosed |
| EP-0174632-B1 | ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF | STERLING DRUG INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4839372-A | ANTIPLAQUE AGENTS | STERLING DRUG INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4839372-A | ANTIPLAQUE AGENTS | STERLING DRUG INC. (US) | 1989-06-13 | — | — | US | disclosed |
| US-4598082-A | DENTISTRY | STERLING DRUG INC. (US) | 1986-07-01 | — | — | US | disclosed |
| US-4598082-A | DENTISTRY | STERLING DRUG INC. (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0174632-A1 | Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof | STERLING DRUG INC. (US) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | SARS1, ACE2, PHOSPHO1 | HSP90AA1 3971/4885KCNA3 273/4885PTGS1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.